TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05503641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive and psychomotor stimulation
Description: Each cognitive stimulation session aimed to maintain and/or improve cognition through memory, language, executive functions, attention, concentration, and perception activities. All the people in the two groups performed the same cognitive stimulation activities adapted to their cognitive and sensory abilities.~The psychomotricity sessions were aimed at maintaining and/or improving the motor, cognitive, social and affective functioning of the person through activities that work on postural tone, body scheme, laterality, fine and gross motor skills, balance, flexibility, among others, adding a cognitive component. All the psychomotricity activities were adapted to the motor and cognitive abilities of the users.
Study: NCT05324410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-840
Description: Solution for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-840 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to VX-840 for oral administration.
Study: NCT06634238

Intervention type: OTHER
Intervention: Incremental shuttle walk test
Description: Participants were recommended to wear comfortable clothing and appropriate shoes for the test. To minimize variability, one masked and one unmasked ISWT was performed on the same participant at the same time of day, one day apart
Study: NCT05977374

Intervention type: OTHER
Group type: OTHER
Intervention: experimental and conventional group
Description: Static stretchings of the lower limb, Ultrasound 1 MHz 1.5W/cm2 7 mins, knee isometrics, open chain activities, knee mobilizations grade 1 and 2, and home care plan.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental and conventional group
Description: Static stretchings of the lower limb, Ultrasound 1 MHz 1.5W/cm2 7 mins, knee isometrics, open chain activities, knee mobilizations grade 1 and 2, and home care plan.
Study: NCT05112913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 2
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 2
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 3
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 2 of the workshop 3
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 3 of the workshop 3
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 1
Description: 600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection
Study: NCT04604067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Cohort A: 6 cycles of acalabrutinib-R-CHOP~Cohort B: 2 cycles of R-CHOP and 2 cycles of acalabrutinb-R-CHOP followed by 2 cycles of acalabrutinib single agent~Cohort C: 4 cycles of R-CHOP followed by 2 cycles of rituximab single agent~Cohort D: 6 cycles of R-CHOP~Rituximab 375 mg/m2 IV Day 1, cyclophosphamide 750 mg/m2 IV Day 1, doxorubicin 50 mg/m2 IV Day 1, vincristine 1.4 mg/m2 (maximum 2 mg) IV Day 1; prednisone 100 mg PO d1-5; Acalabrutinib 100 mg BID Day 1-21, cycles repeated every 21 days
Study: NCT05863052

Intervention type: BIOLOGICAL
Intervention: Immunotherapy
Description: immunotherapy

Intervention type: BIOLOGICAL
Intervention: Immunotherapy
Description: immunotherapy
Study: NCT05564715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroElectric StarStim
Description: 10 sessions of active stimulation (1 mA anodal HD-tDCS targeting preSMA/dACC for 20 min) across 2 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroElectric StarStim
Description: 10 sessions of active stimulation (1 mA anodal HD-tDCS targeting preSMA/dACC for 20 min) across 2 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Sham stimulation for 10 sessions over 2 weeks
Study: NCT06599567

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nintendo Wİİ
Description: Cold - Hot pack applications, TENS device application, which is a pain-relieving electrotherapy agent, therapeutic exercises, games involving your relevant shoulder such as boxing and bowling on the Nintendo Wii game console.
Study: NCT06604416

Intervention type: OTHER
Intervention: Forward walking
Description: The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate forward walking.

Intervention type: OTHER
Intervention: Backward walking
Description: The exercises consisted of a 5-minute warm-up on a treadmill followed by a 25-minute period of moderate backward walking.
Study: NCT06605092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional stimulation
Description: Presentation of the paintings by distinguishing 3 conditions: (1) contemplating each painting (visual stimulation), (2) listening to the original music composed from each painting (auditory stimulation), (3) contemplating and listening to the association of each painting with each specific music (bimodal stimulation)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional stimulation
Description: Presentation of the paintings by distinguishing 3 conditions: (1) contemplating each painting (visual stimulation), (2) listening to the original music composed from each painting (auditory stimulation), (3) contemplating and listening to the association of each painting with each specific music (bimodal stimulation)
Study: NCT06608810

Intervention type: DRUG
Group type: OTHER
Intervention: nerve block with 0.5% ropivacaine
Description: General anesthesia tracheal intubation was used. Induction was performed with midazolam 0.05ml/kg, etomidate 0.3-0.4mg/kg, sufentanil 0.3μg/kg-0.4μg/kg, and rocuronium bromide 0.8mg/kg, and after sufficient oxygen and denitration, the tracheal tube was placed by visual laryngoscopy, and the position of the tube was determined by auscultation of the lungs to determine the position of the catheter, and the respiratory sounds of the sides were symmetrically clear, so that the catheter was fixed and mechanical ventilation was performed. Anesthesia was maintained with remifentanil 0.1～0.3μg/(kg-min), propofol 2\~4mg/(kg-h) rate microinfusion pump for continuous infusion. BIS was kept between 40\~60. Intraoperative rocuronium bromide was given intermittently to maintain muscle relaxation. Perioperative fluid replacement followed the (4:2:1) rule in all patients. For maintenance of hemodynamic stability, ephedrine or atropine was administered, at the anesthesiologist's discretion, if verified a
Study: NCT04749368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-835 (VIR-2218)
Description: BRII-835 (VIR-2218) will be given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-835 (VIR-2218)
Description: BRII-835 (VIR-2218) will be given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-835 (VIR-2218)
Description: BRII-835 (VIR-2218) will be given by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-179 (VBI-2601) with IFN-α
Description: BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-179 (VBI-2601)
Description: BRII-179 (VBI-2601) will be administered by intramuscular injection
Study: NCT06361706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-Enhanced Psychoeducational Program for Chronic Pain
Description: Participants undergo eight weekly sessions that include VR to learn pain physiology, mindfulness, and self-management techniques. Each session is 90 minutes, with 15-20 minutes of VR activities designed to complement the educational content. Activities simulate pain management exercises and mindfulness meditation. The program, led by pain management and VR specialists, aims to improve pain management skills, emotional well-being, and quality of life.
Study: NCT06371209

Intervention type: PROCEDURE
Intervention: Modified Amputation
Description: Modified amputation procedure

Intervention type: PROCEDURE
Intervention: Standard Amputation
Description: Standard amputation procedure
Study: NCT04536350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aviptadil 67μg
Description: Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.
Study: NCT06607575

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: 1. The procedure for heel blood collection will be performed.~2. Pain assessment will be performed with the N-PASS scale during and after the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warming
Description: 1. The cotton sock will be warmed under the heater for 3 minutes. The sock will be put on the newborn and taken off after 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration
Description: 1. A rechargeable toothbrush will be prepared for the newborn to whom vibration will be applied. The vibration process will be applied to the midline of the gastrocnemius muscle for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warming and vibration
Description: 1. After the socks are warmed, they will be put on the newborn\&#39;s feet and both warming and vibration will be applied for 3 minutes.~2. The procedure for heel blood collection will be performed.~3. Pain assessment will be performed with the N-PASS scale during and after the procedure.
Study: NCT06607887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV antibiotic
Description: Parenteral prophylactic antibiotics (cefazolin), 1st dose at the time of induction of anesthesia, 2nd dose after 12hs from the surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral antibiotic
Description: Parenteral prophylactic antibiotic (cefazolin), dose at the time of induction of anesthesia and then oral antibiotic for five days postoperative.
Study: NCT04536350

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.9% NaCl solution
Description: Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days
Study: NCT05162300

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)
Description: Same-Day combination of VI Peel applied to the full face, followed by Botox injection per label to the face.
Study: NCT06609668

Intervention type: BIOLOGICAL
Intervention: Additional blood samples
Description: * 2 dry tubes (5 mL)~* 2 EDTA tubes (6 mL)~Performed at inclusion (before any glucocorticoid and/or immunosuppressive treatment) and at follow-up visit (3 months after inclusion)

Intervention type: BIOLOGICAL
Intervention: Additional blood samples
Description: * 2 dry tubes (5 mL)~* 2 EDTA tubes (6 mL)~Performed at inclusion (before any glucocorticoid and/or immunosuppressive treatment) and at follow-up visit (3 months after inclusion)
Study: NCT06665685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioButton Device
Description: BioButton is a remote wearable multi-parameter monitor, to identify gait disturbances that occur as a side effect of polypharmacy. This arm will be the patient wearing the device during their Nursing Home stay for 30-days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Providing Clinical Care with BioButton Device
Description: BioButton is a remote wearable multi-parameter monitor, to identify gait disturbances that occur as a side effect of polypharmacy. This arm will provide care for patients wearing the BioButton device during their Nursing Home stay for 30-days.
Study: NCT06672705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05292222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation
Description: MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
Study: NCT06527391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: choline bitartrate
Description: Daily supplementation for 9 months with 200 mg choline bitartrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo drug
Description: Daily supplementation for 9 months with identical placebo
Study: NCT06330103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Easy EF
Description: AI was integrated into the application smartphone and used smartphone camera to recorded shot VDO clip of heart ultrasound in parasternal long axis view and returned cardiac function result to user.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Easy EF
Description: AI was integrated into the application smartphone and used smartphone camera to recorded shot VDO clip of heart ultrasound in parasternal long axis view and returned cardiac function result to user.
Study: NCT05843903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #BabyLetsMove
Description: The #BabyLetsMove digital health intervention uses a multi-level, systems-change approach. At the systems-level, racially concordant young adult WIC moms will be trained as health coaches. At the person level, adolescent WIC clients will be given empirically supported behavior goals, self-monitoring text messages with automated feedback, tailored skills training materials, a FitBit device, and tailored peer coaching support. The #BabyLetsMove intervention design is based on formative Teen Mom Study findings to build social cognition, affect, and skills to modify 3 concrete, achievable, and easily monitored behavioral targets: (1) Limit television viewing time to less than 2 hours per day; (2) Walk at least 10,000 steps per day; and (3) Do 20 minutes or more of exercise per day.
Study: NCT05668013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574 Dose Regimen A
Description: Subcutaneous (sc) administration using a commercial sc infusion system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574 Dose Regimen A
Description: Subcutaneous (sc) administration using a commercial sc infusion system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574 Dose Regiment B
Description: Subcutaneous (sc) administration using a commercial sc infusion system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48574 Dose Regiment B
Description: Subcutaneous (sc) administration using a commercial sc infusion system
Study: NCT06703333

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Description: * Months 1-3: One ECP cycle (two-consecutive days) every other week for 3 months (12 procedures).~* Months 4-6: One ECP cycle every month for 3 months (6 procedures).~* Total: 18 procedures (within 6 months \~24 weeks).
Study: NCT06731101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Sonar guided block of Stellate Ganglion By Local anathetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticholinergic and Antidepressant Drugs
Description: Tryptizole Librax
Study: NCT06729918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Thoracic lung physical examination will be studied using a virtual reality-based thoracic and lung physical examination learning tool.
Study: NCT05956990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidimensional rehabilitation
Description: Multidimensional lifestyle interventions
Study: NCT02123498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
Study: NCT06485661

Intervention type: DRUG
Group type: OTHER
Intervention: Captopril Tablets
Description: Patients will be given captopril to see effect on global longitudinal strain
Study: NCT04681573

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood tests
Description: Single arm : all NAFLD patients evaluating the FIB4-FS and the eLIFT-FMVCTE with two patient groups considered at inclusion:~Low-risk group (neither metabolic syndrome nor AST ≥35 UI/l): Liver biopsy won't be mandatory in this group because of the very low risk of advanced fibrosis (4%). These patients will be considered as having no-mild F0-2 liver fibrosis and the study visit will be scheduled for clinical data recording, blood sampling, and LSM with Fibroscan. Liver biopsy could still be performed in the low-risk group if the investigator deems it is required for the clinical management of the patient.~At-risk group (presence of a metabolic syndrome and/or AST ≥35 UI/l): Because of the increased prevalence of significant liver lesions in this group, the patients will have a liver biopsy with clinical data recording, blood sampling, and Fibroscan the same day.
Study: NCT04812665

Intervention type: BEHAVIORAL
Intervention: mHealth solution based on emotional and behavioral change techniques
Description: Adhera supports the empowerment of patients with chronic conditions by supporting the acquisition of healthier lifestyles, improved mental wellbeing and grounded on the principles of behavioral change.~The solution is based on incorporating the principles of personalized health education into a mobile platform which is achieved by applying the Integrated Model of Behavioral Change which is further adapted using recommender systems. Emotional and mental health elements, such as stress, resilience, are crucial part in the acquisition of self-management behaviors and will be the main focus of this intervention. Adhera adapts to provide tailored support to specific users' needs.

Intervention type: BEHAVIORAL
Intervention: mHealth solution based on emotional and behavioral change techniques
Description: Adhera supports the empowerment of patients with chronic conditions by supporting the acquisition of healthier lifestyles, improved mental wellbeing and grounded on the principles of behavioral change.~The solution is based on incorporating the principles of personalized health education into a mobile platform which is achieved by applying the Integrated Model of Behavioral Change which is further adapted using recommender systems. Emotional and mental health elements, such as stress, resilience, are crucial part in the acquisition of self-management behaviors and will be the main focus of this intervention. Adhera adapts to provide tailored support to specific users' needs.
Study: NCT05108311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy and therapeutic exercise
Description: 1. Gliding over the deltoid superficial fascia.~2. Anterior-Posterior mobilization of the clavicle.~3. myofascial release of the shoulder joint complex techniques.~4. Myofascial release external rotation with glenohumeral decoaptation will be carry out in prone position facility the triangular space, quadrangular space and triceps hiatus.~5. anterior and posterior, superior and inferior glenohumeral inferior glide mobilization in adduction will perform in a prone position to facilitate glenohumeral re centration.~6. scapular musculature myofascial release including mobilization with a scapulothoracic joint decoaptation, and angular of the scapula.~7. Supine mobilization of the posterior capsule in 90º shoulder flexion and the adduction.~Finally the patient will be instructed to adapt the daily active biological stimulus at home to maximize the benefits of the manual therapy
Study: NCT03865498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twitter for Hispanic caregivers
Description: This group will be asked to follow and use (i.e., retweet, reply, like) our Hispanic Twitter network for social support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twitter for African American caregivers
Description: This group will be asked to follow and use (i.e., retweet, reply, like) our African American Twitter network for social support.
Study: NCT05485116

Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.

Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
Study: NCT02123498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: 300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24-Hour Diagnostic pH-Probe Test
Description: Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy
Description: Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.